The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
Open accessAbstract
Alzheimer's disease (AD) has characteristic histopathological, molecular, and biochemical abnormalities, including cell loss; abundant neurofibrillary tangles; dystrophic neurites; amyloid precursor protein, amyloid-β (APP-Aβ) deposits; increased activation of prodeath genes and signaling pathways; impaired energy metabolism; mitochondrial dysfunction; chronic oxidative stress; and DNA damage. Gaining a better understanding of AD pathogenesis will require a framework that mechanistically interlinks all these phenomena. Currently, there is a rapid growth in the literature pointing toward insulin deficiency and insulin resistance as mediators of AD-type neurodegeneration, but this surge of new information is riddled with conflicting and unresolved concepts regarding the potential contributions of type 2 diabetes mellitus (T2DM), metabolic syndrome, and obesity to AD pathogenesis. Herein, we review the evidence that (1) T2DM causes brain insulin resistance, oxidative stress, and cognitive impairment, but its aggregate effects fall far short of mimicking AD; (2) extensive disturbances in brain insulin and insulin-like growth factor (IGF) signaling mechanisms represent early and progressive abnormalities and could account for the majority of molecular, biochemical, and histopathological lesions in AD; (3) experimental brain diabetes produced by intracerebral administration of streptozotocin shares many features with AD, including cognitive impairment and disturbances in acetylcholine homeostasis; and (4) experimental brain diabetes is treatable with insulin sensitizer agents, i.e., drugs currently used to treat T2DM. We conclude that the term “type 3 diabetes” accurately reflects the fact that AD represents a form of diabetes that selectively involves the brain and has molecular and biochemical features that overlap with both type 1 diabetes mellitus and T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are many different risk factors that increase the likelihood of a person developing AD, with one of the more significant factors being cardiovascular risk factors, such as Type 2 diabetes.”
From Primary Cilia and Cardiovascular Risk Factors in Alzheimer's Disease (2025) · cites this paper as [81]
In the citing paper
“researchers have used the term “type 3 diabetes”, first proposed over a decade ago, [74] to refer to Alzheimer’s disease due to the plethora of shared mechanisms implicated both in AD and type 1 and type 2 diabetes mellitus (T1DM and T2DM) [75].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [74]
In the citing paper
“There is activation of prodeath genes and signaling pathways;.Mitochondrial dysfunction occurs, energy metabolism is impaired and chronic oxidative stress is typical along with DNA damage (De la Monte and Wands 2008).”
From Iron, Oxidative Stress and Health (2012) · cites this paper as De la Monte and Wands 2008
Citations
Cites
The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas
Szkudelski, T. (2001) · Physiological Research · doi:10.33549/physiolres.930111 · Cited by 2,876
Regulation of neuronal survival by the serine-threonine protein kinase Akt
Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., & Greenberg, M. E. (1997) · Science · doi:10.1126/science.275.5300.661 · Cited by 2,436
Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes
Ullrich, A., Bell, J. R., Chen, E. Y., Herrera, R., Petruzzelli, L. M., Dull, T. J., Gray, A., Coussens, L., Liao, Y.-C., Tsubokawa, M., et al. (1985) · Nature · doi:10.1038/313756a0 · Cited by 2,251
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
Burgering, B. M. T., & Coffer, P. J. (1995) · Nature · doi:10.1038/376599a0 · Cited by 2,089
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Self-citationStructure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein
Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., Cahill, D. A., Goldstein, B. J., & White, M. F. (1991) · Nature · doi:10.1038/352073a0 · Cited by 1,574
Delcommenne, M., Tan, C., Gray, V., Rue, L., Woodgett, J., & Dedhar, S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11211 · Cited by 1,092
Kulik, G., Klippel, A., & Weber, M. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1595 · Cited by 1,040
Sayre, L. M., Zelasko, D. A., Harris, P. L. R., Perry, G., Salomon, R. G., & Smith, M. A. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052092.x · Cited by 1,007
Increased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950
Research works printed but not linked: 8
- Alvarez-Martínez H, 2002, Rev Gastroenterol Mex, 67, 118
- Herruzo JA Solís, 2006, Rev Esp Enferm Dig, 98, 844
- Biju MP, 1998, Biochem Mol Biol Int, 44, 1
- Cicconetti P, 2004, Recenti Prog Med, 95, 535
- Hoyer S, 1994, J Neural Transm Suppl, 44, 259
- Liu X, 1996, Dementia, 7, 128
- Lopes-Cardozo M, 1989, J Dev Physiol, 12, 117
- Watson GS, 2005, Am J Geriatr Psychiatry, 13, 950
Cited by
Emerging applications of metabolomics in drug discovery and precision medicine
Wishart, D. S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.32 · Cited by 1,488
Machine learning and data mining methods in diabetes research
Kavakiotis, I., Tsave, O., Salifoglou, A., Maglaveras, N., Vlahavas, I., & Chouvarda, I. (2017) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.12.005 · Cited by 1,445
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Pérez, J. M., Evans, A. C., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11934 · Cited by 1,202
“Some of these have been previously associated with vascular/metabolic integrity and neurodegenerative progression 3,31,34,35 .”
Management and Prevention Strategies for Non-communicable Diseases (NCDs) and Their Risk Factors
Budreviciute, A., Damiati, S., Sabir, D. K., Onder, K., Schuller-Goetzburg, P., Plakys, G., Katileviciute, A., Khoja, S., & Kodzius, R. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.574111 · Cited by 946
“Other types of diabetes involve gestational diabetes mellitus, which occurs in pregnant women with glucose intolerance (65), and type 3 diabetes, which is associated with Alzheimer’s disease, where neurons in the brain cannot respond to insulin (66).”
BackgroundThe effects of aging in the hippocampus and cognitive decline
Bettio, L. E. B., Rajendran, L., & Gil-Mohapel, J. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.030 · Cited by 649
“…abnormalities found in the brain during early stages of AD and those observed in metabolic syndrome/type 2 diabetes, led some researchers to propose that this neurodegenerative disease may represent a form of “type 3 diabetes” (de la Monte and Wands, 2008; Kroner, 2009; Steen et al., 2005).”
Metadata
- Authors
- de la Monte, S. M., & Wands, J. R.
- Affiliations
- Author Affiliations: Department of Pathology, Rhode Island Hospital and the Warren Alpert Medical School at Brown University, Providence, Rhode Island
- Brown University (US)
- ORCID
- Wands, Jack R.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2008-11
- Volume
- 2
- Issue
- 6
- Pages
- 1101-1113
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC2769828
- OpenAlex
- W2135148756
- Cited by
- 1,158
- References
- 132
- Citations by year
- 2026: 81 · 2025: 79 · 2024: 68 · 2023: 74 · 2022: 75 · 2021: 100 · 2020: 109 · 2019: 91 · 2018: 74 · 2017: 85 · 2016: 76 · 2015: 54 · 2014: 66 · 2013: 47 · 2012: 29
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, type 3 diabetes, brain insulin resistance, insulin deficiency, insulin-like growth factor signaling, type 2 diabetes, metabolic syndrome, obesity, oxidative stress, mitochondrial dysfunction, amyloid-beta, neurofibrillary tangles, cognitive impairment, neurodegeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alzheimer’s disease is type 3 diabetes—Evidence reviewed. https://app.cochat.ai/papers/10.1177/193229680800200619
- The paper
- de la Monte, S. M., & Wands, J. R. (2008). Alzheimer’s disease is type 3 diabetes—Evidence reviewed. Journal of Diabetes Science and Technology. https://doi.org/10.1177/193229680800200619
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.